# KPV Legal Status: FDA Standing and Compounding Access — KPV peptide > KPV legal status: the KPV peptide is not FDA-approved and is scheduled for FDA Pharmacy Compounding Advisory Committee evaluation in July 2026. How the 503A/503B compounding framework and research-only access work. KPV is not an FDA-approved drug. It is individually named on the agenda of an FDA advisory-committee meeting set for July 23-24, 2026 — a scheduled evaluation, not a decision. Here is what that means, stated present-tense and cited to FDA. ## The short version Plain-English first, because KPV legal status confuses people. KPV is not an FDA-approved medicine for anything — it is sold as a research chemical for lab use. In the United States, pharmacies can sometimes custom-make ("compound") a drug from a raw ingredient, but only if that ingredient clears specific FDA rules. KPV has not cleared them yet. What is true right now is that the FDA has formally put KPV on the agenda of an expert advisory meeting in July 2026 to discuss whether it could eventually be allowed for compounding. That is a scheduled conversation, not a yes. Nothing about KPV's status has changed, and this page does not predict the outcome — it just explains the rules as they stand today. ## KPV's Present-Tense Regulatory Status Stated plainly and present-tense: KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication. FDA approval of a finished drug (through a New Drug Application or Biologics License Application) is a separate question from whether a raw ingredient may be used in pharmacy compounding, and KPV holds neither status today. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance — an active ingredient used as a starting material rather than as an already-approved finished drug — may be used in traditional 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulk drug substances list (the "bulks list"). Substances not yet on that list are evaluated by FDA through a public nomination process, with input from the Pharmacy Compounding Advisory Committee (PCAC). KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. ## The 503A and 503B Compounding Framework Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight with FDA registration and inspection. Under FDA's interim policy, nominated bulk substances were sorted into categories — Category 1 (those FDA does not intend to act against while it continues evaluation, provided the guidance conditions are met) and Category 2 (those FDA identified as raising significant safety risks, which are not covered by that enforcement-discretion policy) [18]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories [17]. Importantly for KPV: the audited FDA reference behind this page does not assign KPV any numbered 503A category, so this site does not state or imply one. KPV's status here is exactly as FDA's public calendar frames it — a bulk substance scheduled for PCAC evaluation. (FDA, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act," and the Section 503A bulks pages.) ## Why KPV Is on the July 2026 PCAC Agenda Access to KPV is under active FDA review and may expand in 2026 — but only as a possibility, and only through a process that has not yet run. The concrete, citable fact is this: KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List," evaluated in both its free base and acetate forms. The same agenda also lists BPC-157, TB-500, and MOTs-C. (FDA, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.") Read that for exactly what it is. A PCAC discussion is advisory and is a step in evaluation — not a listing decision, not a reclassification, and not a change in current status. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC; being on the agenda means KPV is under evaluation, not that any outcome has occurred or is assured. No outcome should be assumed, stated, or dated. This site does not predict what the committee will conclude, and it treats the meeting only as a scheduled discussion of a substance under evaluation. ## How Legally Compounded Peptide Access Works Speaking generally — not about KPV specifically, and not as medical or legal advice — a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office or batch use, sourced from an FDA-registered 503B outsourcing facility. Telehealth can serve as the front-end channel for that prescriber evaluation, but it is a route to a consultation and prescription — not a separate legal status. Telehealth does not expand which substances may be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription. And the framework's gate always applies: a compounder may use a requested ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands. This site names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain any substance outside the lawful framework. ## What This Page Does Not Claim To keep the record clean: this page does not present any reclassification of KPV or related peptides as already done, dated, or certain, and it does not rely on unverified reports — including commercial claims that a group of peptides was "moved back" toward Category 1 in early 2026, or vendor claims that specific peptides were "removed" from Category 2 on particular 2026 dates. As of the audited FDA reference, none of those could be confirmed from an authoritative FDA source, and the FDA agenda still listing KPV, BPC-157, and TB-500 for July 2026 is consistent with their evaluation being ongoing rather than resolved. This is general information about the regulatory landscape. It is not medical or legal advice, and nothing here is an offer to sell or supply any substance. For the studies behind KPV's research profile, see [KPV research and mechanism](/research); for the common questions, see [KPV frequently asked questions](/faq). --- A neon-grid research console reading the KPV record straight — the three-bead Lys-Pro-Val chain traced from PepT1 uptake to NF-kB suppression and logged to its studies, the empty human-trial line and the FDA-under-review standing left lit in plain sight; no clinic behind the grid and nothing here dispensed or sold.